Hepatitis B virus inhibiting compound
The inhibition of HBV DNA polymerase and embedded progeny HBV-DNA by thioguanine derivative compounds solves the problem that existing anti-hepatitis B drugs cannot completely eliminate the virus, significantly improving the virus clearance efficiency and functional cure potential.
Patent Information
- Application Number
- CN202411049317.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2024-07-19
- Filing Date
- 2024-08-01
- Publication Date
- 2024-12-06
AI Technical Summary
The existing anti-hepatitis B drugs can only inhibit HBV replication and cannot completely eliminate the virus. The serological clearance rates of HBsAg and HBeAg are low, and the recurrence rate after stopping the drug is high, so functional cure cannot be achieved.
A class of thioguanine derivative compounds were developed that can inhibit the activity of HBV DNA polymerase and embedded in the growth chain of progeny HBV-DNA, disrupting gene arrangement or stopping its growth and losing biological functions.
This compound not only inhibits the reverse transcription activity of HBV polymerase, but can also be embedded in progeny HBV-DNA, disrupting its gene arrangement or stopping its growth, significantly improving the efficiency of virus clearance and having a lower potential than existing drugs.
Smart Images

Figure CN119080777A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the technical field of antiviral compound research, and particularly relates to a class of compounds that inhibit hepatitis B virus. Background Art
[0004] Currently approved nucleotide compounds can reduce liver inflammation and fibrosis, as well as the incidence of cirrhosis and hepatocellular carcinoma. However, the ideal goal of hepatitis B virus (HBV) treatment is a functional cure, defined as persistently undetectable HBsAg. The disappearance of HBsAg signifies the patient's immunity to HBV. Existing nucleotide anti-HBV drugs only inhibit HBV replication but cannot eliminate the virus. Long-term treatment is required, resulting in low HBsAg and HBeAg serological clearance rates and a high relapse rate after discontinuation of treatment.
[0005] Overview of Hepatitis B Virus (HBV) Replication: The HBV genome, HBV-DNA, is composed of two helical DNA strands forming a circular structure. One of the longer strands, the negative strand, is a complete circle. The other, shorter positive strand, is an unclosed semicircle. After HBV infects liver cells, the unclosed semicircular positive strand uses the same circular negative strand as a template to complete the circle under the catalysis of HBV-DNA polymerase. The HBV genome now forms a complete circular double-stranded DNA, also known as cccDNA. This serves as the "primary template" for HBV replication. Once the template is formed, the HBV uses one of the cccDNA strands as a template, utilizing enzymes in the liver cell and HBV DNA polymerase to replicate the genome segment by segment, generating new progeny HBV-DNA genomes composed of the negative and positive strands. Finally, under the guidance of viral assembly enzymes, the progeny HBV-DNA combines with viral proteins to form new progeny HBV particles.
[0006] The HBV replication process consists of seven steps:
[0007] Adhesion: After HBV virus particles invade the human body, they adhere to the surface of liver cells through their outer membrane (composed of HBsAg surface antigen) and NTCP receptors (sodium taurocholate, co-transporting protein) on liver cells.
[0008] Uncoating: Before the core part of the hepatitis B virus enters the cytoplasm of the liver cell, it must first shed its "nucleocapsid" (composed of the core antigen HBcAg and the e antigen HBeAg).
[0009] Nuclear entry: HBV DNA enters the hepatocyte nucleus from the cytoplasm, where it undergoes further development and forms HBV's "covalently closed circular deoxyribonucleic acid (HBV-cccDNA)." The hepatocyte nucleus has a very strong nuclear membrane, and current hepatitis B treatment drugs are unable to penetrate this membrane and enter the nucleus to kill HBV-cccDNA. However, HBV-cccDNA controls all of the HBV virus's genetic information. Current anti-hepatitis B drugs can only inhibit HBV replication or reproduction. Completely eradicating HBV and achieving "all negative results" is only a dream.
[0010] Transcription: Relying on enzymes in liver cells, HBV-cccDNA transfers all genetic information to mRNA (messenger RNA mRNA).
[0011] Translation: The mRNA that has received all the genetic information of HBV begins to synthesize various viral proteins of HBV, such as HBV outer membrane protein (HBsAg), nucleocapsid protein (HBeAg, HBcAg), HBV-DNA polymerase, etc.
[0012] Reverse transcription: HBV-mRNA is reverse transcribed into HBV-DNA, which is the core part of the HBV virus.
[0013] Assembly: Assemble the parts in steps 5 and 6. Once assembled, the replication of HBV is complete.
[0014] Existing anti-hepatitis B drugs mainly rely on the similarity of their molecular structure with the structure of natural nucleotides. Therefore, they can compete with natural nucleosides for the binding sites of reverse transcriptase, inhibit the reverse transcription activity of HBV polymerase, and thus inhibit HBV DNA synthesis.
[0015] The anti-hepatitis B virus compound of the present invention not only has the ability to inhibit the reverse transcription activity of HBV polymerase like commercially available therapeutic drugs, but can also "impersonate" natural nucleosides and embed into the growing daughter HBV-DNA chain, thereby disrupting the gene arrangement in the growing daughter HBV-DNA chain, or causing it to stop growing and lose all biological properties of the subsequent chain segments.
[0016] The information disclosed in this background technology section is only intended to enhance understanding of the overall background of the invention and should not be regarded as an admission or any form of suggestion that the information constitutes the prior art already known to a person skilled in the art. Summary of the Invention
[0017] The object of the present invention is to provide an antiviral compound to overcome the above-mentioned defects in the prior art.
[0018] To achieve the above objectives, the present invention discloses a compound of formula 1 or a pharmaceutically acceptable ester or salt thereof:
[0019]
[0020] Among them, R1 can choose one of the following:
[0021] The first option: R1 is H or R;
[0022] Second option: R1 is:
[0023]
[0024] where R x and R y Selected from the following types I, II, III, IV, R or OH:
[0025]
[0026] In the second option, R a 、R b 、R c 、R d and R e Each of them may be H, deuterium D, halogen, (C1-C8) alkyl, mono- or poly-substituted (C1-C8) alkyl; (C3-C8) cycloalkyl, mono- or poly-substituted (C3-C8) cycloalkyl; (C1-C8) alkoxy, mono- or poly-substituted (C1-C8) alkoxy; (C3-C8) cycloalkoxy, mono- or poly-substituted (C3-C8) cycloalkoxy; (C6-C 20 ) aryl, monosubstituted or polysubstituted (C6-C 20 ) aryl;
[0027] R2, R3, R4, R5, R6, R7, R8 are each H, deuterium D, a substituent as defined, (C1-C8) alkyl, mono- or poly-substituted (C1-C8) alkyl; (C1-C8) alkoxy, mono- or poly-substituted (C1-C8) alkoxy; (C3-C8) cycloalkyl, mono- or poly-substituted (C3-C8) cycloalkyl; (C3-C8) cycloalkoxy, mono- or poly-substituted (C3-C8) cycloalkoxy; (C2-C8) alkenyl, mono- or poly-substituted (C2-C8) alkenyl; (C2-C8) alkynyl, mono- or poly-substituted (C2-C8) alkynyl; (C6 ... cycloalkyl 20 ) aryl, monosubstituted or polysubstituted (C6-C 20 ) aryl;
[0028] R9, R 10 、R 11 、R 12Each is H, deuterium D or halogen, halogen is F or Cl;
[0029] X is O, S or Se;
[0030] R includes: (C1-C8) alkyl, monosubstituted or polysubstituted (C1-C8) alkyl; (C2-C8) alkenyl, monosubstituted or polysubstituted (C2-C8) alkenyl; (C2-C8) alkynyl, monosubstituted or polysubstituted (C2-C8) alkynyl; (C3-C8) cycloalkyl, monosubstituted or polysubstituted (C3-C8) cycloalkyl; (C3-C8) cycloalkenyl, monosubstituted or polysubstituted (C3-C8) cycloalkenyl; (C6-C 20 ) aryl, monosubstituted or polysubstituted (C6-C 20 ) aryl; 3-8 membered heterocyclic group, monosubstituted or polysubstituted 3-8 membered heterocyclic group, any carbon atom of which can be replaced by -Se-, -NR-, -O- or -S-; (C6-C 20 ) heteroaryl, monosubstituted or polysubstituted (C6-C 20 ) heteroaryl, any carbon atom of which may be replaced by -Se-, -NR-, -O- or -S-; (C6-C 20 ) aryl (C1-C8) alkyl, monosubstituted or polysubstituted (C6-C 20 ) aryl (C1-C8) alkyl; (C6-C 20 )aryl-monosubstituted or polysubstituted (C1-C8)alkyl; monosubstituted or polysubstituted (C6-C 20 )aryl-monosubstituted or polysubstituted (C1-C8)alkyl; (C1-C8)alkyl-(C6-C 20 )aryl, monosubstituted or polysubstituted (C1-C8)alkyl-(C6-C 20 )aryl; (C1-C8)alkyl-monosubstituted or polysubstituted-(C6-C 20 )aryl; monosubstituted or polysubstituted (C1-C8)alkyl-monosubstituted or polysubstituted (C6-C 20 )aryl; HC=O, (C1-C7)alkyl-C=O, mono- or poly-substituted (C1-C7)alkyl-C=O; (C6-C 20 )Aryl-C=O, monosubstituted or polysubstituted (C6-C 20 )Aryl-C=O; (C6-C 20 ) aryloxy, monosubstituted or polysubstituted (C6-C 20 )aryloxy;
[0031] Definition: Substituents or substitutions include halogen, -OH, -OR, -NO2, -N(R)O, -NR2 (each R can be selected from the same element or different elements in the R set), -NH2, -NHR, -CN, -CH=N=N, -CHO, -COOH, -COOR, -SH, -SR, -COSH, -COSR; thiocyanate, oxycyanate, methylcyanate, urea, guanidino;
[0032] The meaning of polysubstituted includes selecting multiple substituents of the same type or selecting multiple substituents of different types;
[0033] Monosubstituted means that only one substituent is selected.
[0034] In the first option, the specific structure of the compound of Formula 1 is the compound shown in Formula 1-A, the compound shown in Formula 1-B, the compound shown in Formula 1-C, and the compound shown in Formula 1-D;
[0035]
[0036] This compound is a derivative of thioguanine. It not only inhibits the polymerase of hepatitis B virus DNA but also has the ability to intercalate into the growing DNA chain of the progeny hepatitis B virus. This intercalation disrupts the normal sequence of nucleotides in the growing progeny hepatitis B virus DNA chain or halts its growth, depriving the remaining portion of the gene of its biological function. The compound of this invention is a product guided by a completely innovative biopolymer condensation theory.
[0037] Preferably, in the above technical solution, when R1 adopts the second option, the specific structure of the compound of Formula 1 is the compound shown in Formula 2, the compound shown in Formula 3, the compound shown in Formula 4, the compound shown in Formula 5, and the compound shown in Formula Xi;
[0038]
[0039]
[0040] wherein X is O, SS or Se;
[0041] R2, R3, R4, R5, R6, R7 and R8 are each H, a substituent as defined, (C1-C8) alkyl, a monosubstituted or polysubstituted (C1-C8) alkyl, (C1-C8) alkoxy, a monosubstituted or polysubstituted (C1-C8) alkoxy, (C3-C8) cycloalkyl, a monosubstituted or polysubstituted (C3-C8) cycloalkyl, (C3-C8) cycloalkoxy, a monosubstituted or polysubstituted (C3-C8) cycloalkoxy, (C2-C8) alkenyl, a monosubstituted or polysubstituted (C2-C8) alkenyl, (C2-C8) alkynyl, a monosubstituted or polysubstituted (C2-C8) alkynyl, (C6-C 20 ) aryl, monosubstituted or polysubstituted (C6-C 20 ) aryl;
[0042] R9, R 10 、R 11 、R 12 Each is H, deuterium D or halogen, and halogen is F or Cl.
[0043] Preferably, in the above technical solution, R4 and R6 can also be independently: (C1-C7) alkyl-C(O)O-, monosubstituted or polysubstituted (C1-C7) alkyl-C(O)O-; (C1-C7) alkoxy-C(O)O-, monosubstituted or polysubstituted (C1-C7) alkoxy-C(O)O-; (C1-C7) alkyl-C(O)-NH-, monosubstituted or polysubstituted (C1-C7) alkyl-C(O)-NH-; (C1-C7) alkoxy-C(O)-NH-, monosubstituted or polysubstituted (C1-C7) alkoxy-C (O)-NH-; (C1-C7)alkyl-C(O)-NR-, monosubstituted or polysubstituted (C1-C7)alkyl-C(O)-NR-; (C1-C7)alkoxy-C(O)-NR-, monosubstituted or polysubstituted (C1-C7)alkoxy-C(O)-NR-; (C1-C7)alkyl-C(O)-S-, monosubstituted or polysubstituted (C1-C7)alkyl-C(O)-S-; (C1-C7)alkoxy-C(O)-S-, monosubstituted or polysubstituted (C1-C7)alkoxy-C(O)-S-; (C6-C 20 )aryl-C(O)O-, mono- or poly-substituted (C6-C 20 )aryl-C(O)O-; (C6-C 20 )aryl-C(O)-NH-, monosubstituted or polysubstituted (C6-C 20 )aryl-C(O)-NH-; (C6-C 20 )aryl-C(O)-NR-, monosubstituted or polysubstituted (C6-C 20 )aryl-C(O)-NR-; (C6-C 20 )aryl-C(O)-S-, monosubstituted or polysubstituted (C6-C20 )aryl-C(O)-S-.
[0044] Preferably, in the above technical solution, R8 is -NH2·HX, and HX is HBr, fumaric acid, and other pharmaceutically acceptable inorganic or organic acids.
[0045] Preferably, in the above technical solution, R2, R3, R4, R5, R6, R7, R8, R9, R 10 、R 11 、R 12 , the specific structure of the compound of formula 2 is the compound shown in formula 2-A1, the compound shown in formula 2-A2, the compound shown in formula 2-A3, the compound shown in formula 2-A4, the compound shown in formula 2-A5 and the compound shown in formula 2-B, the specific structure of the compound of formula 3 is the compound shown in formula 3-A and the compound shown in formula 3-B, the specific structure of the compound of formula 4 is the compound shown in formula 4-A1, the compound shown in formula 4-A2 and the compound shown in formula 4-B, the specific structure of the compound of formula 5 is the compound shown in formula 5-A and the compound shown in formula 5-B, and the specific structure of the compound shown in formula xi is the compound shown in formula xi-A1, the compound shown in formula xi-A2, the compound shown in formula xi-A3 and the compound shown in formula xi-A4;
[0046]
[0047]
[0048] Preferably, in the above technical solution, the OH group at the 3' position is replaced with an F group, and the compound represented by formula 2-C1, the compound represented by formula 2-C2, the compound represented by formula 3-C, the compound represented by formula 4-C1, and the compound represented by formula 5-C can be obtained from the compound represented by formula 2-A1, the compound represented by formula 2-A2, the compound represented by formula 3-A, the compound represented by formula 4-A1, and the compound represented by formula 5-A;
[0049]
[0050] Preferably, in the above technical solution, the OH group at the 3' position is replaced with an F group, and the compound represented by formula 2-D, the compound represented by formula 3-D, the compound represented by formula 4-D, and the compound represented by formula 5-D can be obtained from the compound represented by formula 2-B, the compound represented by formula 3-B, the compound represented by formula 4-B, and the compound represented by formula 5-B;
[0051]
[0052]
[0053] Preferably, in the above technical solution, the ribose structure in Formula 1 is selected from the following:
[0054]
[0055] Wherein R2, R3, R4, R5, R6, and R7 are each a “substituent” as defined in the definition, (C1-C8)alkyl, monosubstituted or polysubstituted (C1-C8)alkyl; (C1-C8)alkoxy, monosubstituted or polysubstituted (C1-C8)alkoxy; (C3-C8)cycloalkyl, monosubstituted or polysubstituted (C3-C8)cycloalkyl; (C3-C8)cycloalkoxy, monosubstituted or polysubstituted (C3-C8)cycloalkoxy; (C2-C8)alkenyl, monosubstituted or polysubstituted (C2-C8)alkenyl; (C2-C8)alkynyl, monosubstituted or polysubstituted (C2-C8)alkynyl; (C6-C8) 20 ) aryl, monosubstituted or polysubstituted (C6-C 20 ) aryl; R9, R 10 Each is H, deuterium (D) or halogen, halogen is F or Cl;
[0056]
[0057] wherein X is -O- or -S- or -Se-; R2, R5, R6, and R7 are each a "substituent" as defined in the definition, (C1-C8) alkyl, monosubstituted or polysubstituted (C1-C8) alkyl; (C1-C8) alkoxy, monosubstituted or polysubstituted (C1-C8) alkoxy; (C3-C8) cycloalkyl, monosubstituted or polysubstituted (C3-C8) cycloalkyl; (C3-C8) cycloalkoxy, monosubstituted or polysubstituted (C3-C8) cycloalkoxy; (C2-C8) alkenyl, monosubstituted or polysubstituted (C2-C8) alkenyl; (C2-C8) alkynyl, monosubstituted or polysubstituted (C2-C8) alkynyl; (C6-C8) 20 ) aryl, monosubstituted or polysubstituted (C6-C 20 ) aryl; R9, R 10 Each is H, deuterium D or halogen, and halogen is F or Cl.
[0058]
[0059] R3 (except the -OH group in the substituent), R5, R6, and R7 are each a "substituent" as defined, (C1-C8) alkyl, monosubstituted or polysubstituted (C1-C8) alkyl; (C1-C8) alkoxy, monosubstituted or polysubstituted (C1-C8) alkoxy; (C3-C8) cycloalkyl, monosubstituted or polysubstituted (C3-C8) cycloalkyl; (C3-C8) cycloalkoxy, monosubstituted or polysubstituted (C3-C8) cycloalkoxy; (C2-C8) alkenyl, monosubstituted or polysubstituted (C2-C8) alkenyl; (C2-C8) alkynyl, monosubstituted or polysubstituted (C2-C8) alkynyl; (C6-C 20 ) aryl, monosubstituted or polysubstituted (C6-C 20 ) aryl; R3 except -OH group in substituent; R9, R 10 Each is H, deuterium (D) or halogen, and halogen is F or Cl.
[0060]
[0061] Wherein R3, R5 (except -OH in the substituent), R2, and R7 are each a "substituent" as defined, (C1-C8) alkyl, monosubstituted or polysubstituted (C1-C8) alkyl; (C1-C8) alkoxy, monosubstituted or polysubstituted (C1-C8) alkoxy; (C3-C8) cycloalkyl, monosubstituted or polysubstituted (C3-C8) cycloalkyl; (C3-C8) cycloalkoxy, monosubstituted or polysubstituted (C3-C8) cycloalkoxy; (C2-C8) alkenyl, monosubstituted or polysubstituted (C2-C8) alkenyl; (C2-C8) alkynyl, monosubstituted or polysubstituted (C2-C8) alkynyl; (C6 ... 20 ) aryl, monosubstituted or polysubstituted (C6-C 20 ) aryl; R5 excludes -OH group in the substituent; R9, R 10 Each is H, deuterium (D) or halogen, and halogen is F or Cl.
[0062] Preferably, in the above technical solution, any corresponding molecular structure can produce four corresponding derivatives due to the different molecular structures of the ribose moiety. Taking Formula 2-C1 as an example, Formula 2-C1 / a, Formula 2-C1 / b, Formula 2-C1 / c, and Formula 2-C1 / d can be derived.
[0063]
[0064] A pharmaceutical composition comprises the compound of formula 1 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
[0065] Use of the aforementioned nucleoside phosphate or a pharmaceutically acceptable salt thereof or the pharmaceutical composition in the preparation of a drug for inhibiting hepatitis B virus.
[0066] It should be noted that when the phosphorus atom and the carbon atom are connected to four different groups, the phosphorus atom and the carbon atom have chirality, and the above-mentioned compounds involving chiral phosphorus and chiral carbon should include optically active isomers of R, S configuration.
[0067] In the above-mentioned compounds, H, C, O, N, P, S and halogen atoms all have isotopes. When reading this patent, researchers should be aware that the compounds described in this patent should include compounds composed of their isotopes.
[0068] Compared with the prior art, the present invention has the following beneficial effects:
[0069] The anti-hepatitis B virus compound of the present invention not only has the ability to inhibit the reverse transcription activity of HBV polymerase like commercially available therapeutic drugs, but can also "impersonate" natural nucleosides and embed into the growing daughter HBV-DNA chain, thereby disrupting the gene arrangement in the growing daughter HBV-DNA chain, or causing it to stop growing and lose all biological properties of the subsequent chain segments. BRIEF DESCRIPTION OF THE DRAWINGS
[0070] Figure 1 This is the NMR spectrum of compound A2-A;
[0071] Figure 2 This is the NMR spectrum of compound A2-B;
[0072] Figure 3 This is the NMR spectrum of compound A2-C;
[0073] Figure 4 This is a bar chart of the efficacy results. DETAILED DESCRIPTION
[0074] The specific embodiments of the present invention are described in detail below, but it should be understood that the protection scope of the present invention is not limited by the specific embodiments.
[0075] Unless expressly stated otherwise, throughout the specification and claims, the term "comprise" or variations such as "include" or "comprising", etc., will be understood to include the stated elements or components but not to exclude other elements or other components.
[0076] Example 1 Synthesis of Compound A2-A:
[0077]
[0078] Compound A (10.0 g, 36.1 mmol) was dissolved in pyridine (80 mL) and placed in an ice bath. TIPDSCl (17.0 g, 53.9 mmol) was added dropwise under nitrogen, and the mixture was warmed to room temperature and stirred overnight. After completion of the reaction, ice water (200 mL) was added and stirred until all solids precipitated. The filter cake was filtered and purified by column chromatography (DCM / MeOH = 20 / 1) to obtain compound B (16.0 g, white solid, 85% yield).
[0079] Compound B (12.0 g, 23.1 mmol) was dissolved in pyridine (80 mL) and placed in an ice bath. TFAA (38.8 g, 184.7 mmol) was added under nitrogen and stirred for 40 min under ice bath conditions. After monitoring the reaction, NaSH (12.9 g, 230.1 mmol) was dissolved in DMF (100 mL) and then slowly added to the reaction mixture of Compound B. The mixture was stirred at room temperature overnight. After completion of the reaction, an appropriate amount of water was added to quench the reaction, and the mixture was extracted with ethyl acetate. The organic phase was concentrated and filtered through a column to obtain Compound C (6.2 g, yellow solid, 50% yield).
[0080] Compound C (6.0 g, 11.2 mmol) was dissolved in THF (60 mL) and placed in an ice bath. TBAF (22.4 mL, 22.4 mmol, 1 M in THF) was added under nitrogen and stirred at room temperature for 2 h. After completion of the reaction, the reaction solution was concentrated, slurried with methanol, and filtered. The filter cake was dried to obtain product A2-A (2.3 g, off-white solid, 70% yield).
[0081] 1 H-NMR (400MHz, DMSO-d6): δ11.90 (s, 1H), 7.88 (s, 1H), 6.77 (s, 2H), 5.35 (t, 1H), 5.13 (s, 1H), 4.91 -4.84(m, 2H), 4.60(s, 1H), 4.24(s, 1H), 3.54(t, 2H), 2.53(s, 1H), 2.27-2.20(m, 1H), 2.05(t, 1H).
[0082] Example 2 Synthesis of Compound A2-B:
[0083]
[0084] Compound A2-A (800 mg, 2.73 mmol) was dissolved in NMP (25 mL) and placed in an ice bath. t-BuMgCl (8.2 mL, 8.2 mmol, 1 M in THF) was added under nitrogen and stirred in the ice bath for 30 min. A solution of compound D (CAS: 1354823-36-1, 2.5 g, 5.55 mmol) in THF (10 mL) was added to the reaction mixture and stirred at room temperature overnight. After completion, the reaction was quenched with ice water and extracted with ethyl acetate. The organic phase was concentrated and purified on a silica gel column (DCM / MeOH = 20 / 1) to afford impure A2-B. Further purification on a C18 column afforded A2-B (514 mg, white solid, 31% yield).
[0085] 1 H-NMR (400MHz, DMSO-d6): δ11.91 (s, 1H), 7.86 (s, 1H), 7.36 (t, 2H), 7.24-7. 16(m, 3H), 6.76(s, 2H), 6.05(m, 1H), 5.38(t, 1H), 5.18(s, 1H), 5.07(d, 1H), 4.64(s, 1H), 4.24-4.20(m, 2H), 4.09-3.87(m, 4H), 2.75(s, 1H), 2.33-2.26( m, 1H), 2.10-2.05 (m, 1H), 1.48-1.43 (m, 1H), 1.33-1.25 (m, 7H), 0.83 (t, 6H).
[0086] Synthesis of compound A2-C:
[0087]
[0088] Compound E (3.0 g, 23.2 mmol) was dissolved in compound F (50 mL), and TMSCl (15.2 g, 139.9 mmol) was added. The mixture was stirred at 70°C overnight. After the reaction was completed, the reaction solution was concentrated, and petroleum ether was added and concentrated for 2 to 3 times to obtain compound G (4.6 g, light yellow oil, yield 93%).
[0089] Phenyl dichlorophosphate (4.2 g, 19.9 mmol) was dissolved in DCM (30 mL), and pentafluorophenol (4.4 g, 23.9 mmol) and triethylamine (6.0 g, 59.3 mmol) were added. The mixture was stirred at 40°C for 1 h. Compound G (4.6 g, 21.6 mmol) was dissolved in DCM (30 mL) and added to the reaction mixture, followed by stirring for 3 h. After completion of the reaction, the reaction mixture was concentrated and purified by column chromatography to obtain Compound H (1.8 g, colorless oil, 16% yield).
[0090] Compound A2-A (878 mg, 3.0 mmol) was dissolved in NMP (20 mL) and placed in an ice bath. t-BuMgCl (6.0 mL, 6.0 mmol, 1 M in THF) was added under nitrogen and stirred for 30 min while maintaining the ice bath. A solution of compound H (1.6 g, 3.0 mmol) in THF (10 mL) was then added to the reaction mixture and stirred at room temperature for 3 h. After completion of the reaction, the mixture was quenched with water and extracted with ethyl acetate. The organic phase was concentrated and purified by column chromatography (DCM / MeOH = 20 / 1) to afford compound A2-C (impure). This was further purified by C18 to afford compound A2-C (630 mg, white solid, 33% yield).
[0091] 1 H-NMR (400MHz, DMSO-d6): δ11.91 (s, 1H), 7.85 (dd, 1H), 7.36 (dd, 2H), 7.25-7. 14(m, 3H), 6.75(s, 2H), 5.63(d, 1H), 5.37(t, 1H), 5.16(d, 1H), 5.08-5.01(m, 1 H), 4.65(d, 1H), 4.29-3.87(m, 5H), 2.78(t, 1H), 2.43-2.22(m, 1H), 2.07(t, 1H) ), 1.52-1.43 (m, 1H), 1.34-1.18 (m, 8H), 0.86-0.76 (m, 6H), 0.47-0.31 (m, 4H).
[0092] Example 4 In vitro anti-HBV activity study
[0093] 1. Experimental Procedure
[0094] 3.1 Preparation of main solution
[0095] 3.1.1 Preparation of culture medium: Prepare DMEM culture medium containing 10% fetal bovine serum.
[0096] 3.1.2 Preparation of drug-containing culture medium: Use culture medium to prepare samples of agreed concentration (cytotoxicity and efficacy testing).
[0097] 3.2 Experimental steps
[0098] With 10 5 HepG2.2.15 cells were inoculated with 10% fetal bovine serum DMEM culture medium at 37 degrees and 5% CO2. After culturing for 24 hours, different concentrations of samples were added for intervention and incubated for 6 days (drug-containing culture medium was replaced on the 3rd day). The supernatant was taken to detect HBV-DNA levels and compared with the supernatant of HepG2.2.15 cells without intervention.
[0099] 2. Experimental Results
[0100] HBV-DNA test results
[0101] The drug was incubated for 6 days, and the test results are shown in Table 1. Figure 4 .
[0102] Table 1 Inhibitory effect of samples on HBV-DNA (6 days)
[0103]
[0104] 3. Experimental Conclusion
[0105] Inhibition of HBV DNA secretion in viral particles: All samples inhibited HBV DNA secretion in supernatant viral particles within the specified range. The IC50 for entecavir was 5.42 nM. A2-A, B, and C all inhibited HBV DNA secretion, with A2-B exhibiting a greater inhibitory effect than entecavir, achieving 50% inhibition at 0.8 nM. The IC50 calculated from three doses, 0.8-20 nM, was 1.04 nM.
[0106] Based on the in vitro efficacy results of A2-B, compound A2-B has the potential to be developed into an anti-HBV therapeutic drug with a lower dosage and better therapeutic efficacy than entecavir. It will preferably be formulated into an oral medication in the form of tablets, capsules, granules, or powder.
[0107] The foregoing descriptions of specific exemplary embodiments of the present invention are for purposes of illustration and description. These descriptions are not intended to limit the invention to the precise forms disclosed, and it is apparent that many variations and modifications are possible in light of the foregoing teachings. The exemplary embodiments have been selected and described for the purpose of explaining the specific principles of the invention and their practical application, thereby enabling those skilled in the art to realize and utilize a variety of exemplary embodiments of the invention and various options and modifications. The scope of the invention is intended to be defined by the claims and their equivalents.
Claims
1. A compound of formula 1 or a pharmaceutically acceptable ester or salt thereof: Where R 1 Choose one of the following: First option: R 1 is H or R; Second option: R 1 for: Where R x and R y Selected from the following types I, II, III, IV, R or OH: In the second option, R a , R b , R c , R d and R e can be H, deuterium D, halogen, (C 1 -C 8 ) alkyl, monosubstituted or polysubstituted (C 1 -C 8 ) alkyl; (C 3 -C 8 )cycloalkyl, mono- or poly-substituted (C 3 -C 8 )cycloalkyl; (C 1 -C 8 ) alkoxy, mono- or poly-substituted (C 1 -C 8 ) alkoxy; (C 3 -C 8 )cycloalkoxy, mono- or poly-substituted (C 3 -C 8 )cycloalkoxy; (C 6 -C 20 ) aryl, monosubstituted or polysubstituted (C 6 -C 20 ) aryl; R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 Each is H, deuterium D, a substituent in the definition, (C 1 -C 8 ) alkyl, monosubstituted or polysubstituted (C 1 -C 8 ) alkyl; (C 1 -C 8 ) alkoxy, mono- or poly-substituted (C 1 -C 8 ) alkoxy; (C 3 -C 8 )cycloalkyl, mono- or poly-substituted (C 3 -C 8 )cycloalkyl; (C 3 -C 8 )cycloalkoxy, mono- or poly-substituted (C 3 -C 8 )cycloalkoxy; (C 2 -C 8 )alkenyl, monosubstituted or polysubstituted (C 2 -C 8 ) alkenyl; (C 2 -C 8 ) alkynyl, mono- or polysubstituted (C 2 -C 8 ) alkynyl; (C 6 -C 20 ) aryl, monosubstituted or polysubstituted (C 6 -C 20 ) aryl; R 9 , R 10 , R 11 , R 12 Each is H, deuterium D or halogen, halogen is F or Cl; X is O or S or Se; R contains: (C 1 -C 8 ) alkyl, monosubstituted or polysubstituted (C 1 -C 8 ) alkyl; (C 2 -C 8 )alkenyl, monosubstituted or polysubstituted (C 2 -C 8 ) alkenyl; (C 2 -C 8 ) alkynyl, mono- or polysubstituted (C 2 -C 8 ) alkynyl; (C 3 -C 8 )cycloalkyl, mono- or poly-substituted (C 3 -C 8 )cycloalkyl; (C 3 -C 8 )cycloalkenyl, mono- or poly-substituted (C 3 -C 8 )cycloalkenyl; (C 6 -C 20 ) aryl, monosubstituted or polysubstituted (C 6 -C 20 ) aryl; 3-8 membered heterocyclic group, monosubstituted or polysubstituted 3-8 membered heterocyclic group, any carbon atom of which can be replaced by -Se-, -NR-, -O- or -S-; (C 6 -C 20 ) heteroaryl, monosubstituted or polysubstituted (C 6 -C 20 ) heteroaryl, any carbon atom of which may be replaced by -Se-, -NR-, -O- or -S-; (C 6 -C 20 )Aryl (C 1 -C 8 ) alkyl, monosubstituted or polysubstituted (C 6 -C 20 )Aryl (C 1 -C 8 ) alkyl; (C 6 -C 20 )Aryl-monosubstituted or polysubstituted (C 1 -C 8 ) alkyl; monosubstituted or polysubstituted (C 6 -C 20 )Aryl-monosubstituted or polysubstituted (C 1 -C 8 ) alkyl; (C 1 -C 8 )alkyl-(C 6 -C 20 ) aryl, monosubstituted or polysubstituted (C 1 -C 8 )alkyl-(C 6 -C 20 ) aryl; (C 1 -C 8 )alkyl-monosubstituted or polysubstituted-(C 6 -C 20 ) aryl; monosubstituted or polysubstituted (C 1 -C 8 )alkyl-monosubstituted or polysubstituted (C 6 -C 20 )aryl; HC=O, (C 1 -C 7 )alkyl-C=O, monosubstituted or polysubstituted (C 1 -C 7 )alkyl-C=O; (C 6 -C 20 )Aryl-C=O, monosubstituted or polysubstituted (C 6 -C 20 )Aryl-C=O; (C 6 -C 20 ) aryloxy, mono- or poly-substituted (C 6 -C 20 )aryloxy; Definition: Substituent or substitution, including halogen, -OH, -OR, -NO 2 、-N(R)O、-NR 2 (Each R can select the same element from the R set, or it can select different elements), -NH 2 , -NHR, -CN, -CH=N=N, -CHO, -COOH, -COOR, -SH, -SR, -COSH, -COSR; thiocyanate, oxycyanate, methylcyanate, urea, guanidinium; The meaning of polysubstitution includes selecting multiple substituents of the same kind or selecting multiple substituents of different kinds; Monosubstituted means only one substituent is selected.
2. The compound according to claim 1, Features: When R1 adopts the first option, the specific structure of the compound of Formula 1 is the compound shown in Formula 1-A, the compound shown in Formula 1-B, the compound shown in Formula 1-C, and the compound shown in Formula 1-D; 3. The compound according to claim 1, Features: When R1 adopts the second option, the specific structure of the compound of formula 1 is the compound shown in formula 2, the compound shown in formula 3, the compound shown in formula 4, the compound shown in formula 5, and the compound shown in formula Xi; wherein X is O, S or Se; R 2 , R 3 , R 4 , R 5 , R 6 , R 7 and R 8 Select H, the substituent in the definition, (C 1 -C 8 ) alkyl, monosubstituted or polysubstituted (C 1 -C 8 ) alkyl, (C 1 -C 8 ) alkoxy, mono- or poly-substituted (C 1 -C 8 ) alkoxy, (C 3 -C 8 )cycloalkyl, mono- or poly-substituted (C 3 -C 8 )cycloalkyl, (C 3 -C 8 )cycloalkoxy, Single or multiple substitution (C 3 -C 8 )cycloalkoxy, (C 2 -C 8 )alkenyl, monosubstituted or polysubstituted (C 2 -C 8 ) Alkenyl, (C 2 -C 8 ) alkynyl, mono- or polysubstituted (C 2 -C 8 ) alkynyl, (C 6 -C 20 ) aryl, monosubstituted or polysubstituted (C 6 -C 20 ) aryl; R 9 , R 10 , R 11 , R 12 Each is H, deuterium D or halogen, and halogen is F or Cl.
4. The compound according to claim 1 or 3, Features: R 4 and R 6 They can also be: (C 1 -C 7 )alkyl-C(O)O-, mono- or poly-substituted (C 1 -C 7 )alkyl-C(O)O-; (C 1 -C 7 )alkoxy-C(O)O-, mono- or poly-substituted (C 1 -C 7 )alkoxy-C(O)O-; (C 1 -C 7 )alkyl-C(O)-NH-, mono- or poly-substituted (C 1 -C 7 )alkyl-C(O)-NH-; (C 1 -C 7 )alkoxy-C(O)-NH-, mono- or poly-substituted (C 1 -C 7 )alkoxy-C(O)-NH-; (C 1 -C 7 )alkyl-C(O)-NR-, mono- or poly-substituted (C 1 -C 7 )alkyl-C(O)-NR-; (C 1 -C 7 )alkoxy-C(O)-NR-, mono- or poly-substituted (C 1 -C 7 )alkoxy-C(O)-NR-; (C 1 -C 7 )alkyl-C(O)-S-, mono- or poly-substituted (C 1 -C 7 )alkyl-C(O)-S-; (C 1 -C 7 )alkoxy-C(O)-S-, mono- or poly-substituted (C 1 -C 7 )alkoxy-C(O)-S-; (C 6 -C 20 )aryl-C(O)O-, mono- or poly-substituted (C 6 -C 20 )aryl-C(O)O-; (C 6 -C 20 )aryl-C(O)-NH-, mono- or poly-substituted (C 6 -C 20 )aryl-C(O)-NH-; (C 6 -C 20 )aryl-C(O)-NR-, mono- or poly-substituted (C 6 -C 20 )aryl-C(O)-NR-; (C 6 -C 20 )aryl-C(O)-S-, mono- or poly-substituted (C 6 -C 20 )Aryl-C(O)-S-.
5. The compound according to claim 1 or 3, Features: R 8 Also -NH 2 HX, HX is HBr, fumaric acid and other pharmaceutically acceptable inorganic or organic acids.
6. The compound according to claim 3, Features: Choose R appropriately 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12 The specific structure of the compound of formula 2 is formula 2-A 1 The compound shown, 2-A 2 The compound shown, 2-A 3 The compound shown, 2-A 4 The compound shown, 2-A 5 The specific structure of the compound of formula 3 is the compound of formula 3-A and the compound of formula 3-B, and the specific structure of the compound of formula 4 is the compound of formula 4-A 1 The compound shown in formula 4-A 2 The specific structure of the compound of formula 5 is the compound of formula 5-A and the compound of formula 5-B, and the specific structure of the compound of formula xi is the compound of formula xi-A 1 The compound shown, formula xi-A 2 The compound shown, formula xi-A 3 The compound shown, formula xi-A 4 The compounds shown; 7. The compound according to claim 6, Features: If the OH group at the 3' position is replaced by an F group, then the formula 2-A 1 The compound shown in formula 2-A 2 The compound shown in formula 3-A, the compound shown in formula 4-A 1 The compound shown in formula 5-A is obtained by 1 The compound shown in formula 2-C 2 The compound shown in formula 3-C, the compound shown in formula 4-C 1 The compound shown, the compound shown in formula 5-C; 8. The compound according to claim 6, Features: By replacing the OH group at the 3' position with an F group, the compound of formula 2-D, the compound of formula 3-D, the compound of formula 4-D, and the compound of formula 5-D can be obtained from the compound of formula 2-B, the compound of formula 3-B, the compound of formula 4-B, and the compound of formula 5-B; 9. The compound according to claim 1, Features: In formula 1, one of the ribose structures is selected as follows: Where R 2 , R 3 , R 4 , R 5 , R 6 , R 7 Each is a "substituent" in the definition, (C 1 -C 8 ) alkyl, monosubstituted or polysubstituted (C 1 -C 8 ) alkyl; (C 1 -C 8 ) alkoxy, mono- or poly-substituted (C 1 -C 8 ) alkoxy; (C 3 -C 8 )cycloalkyl, mono- or poly-substituted (C 3 -C 8 )cycloalkyl; (C 3 -C 8 )cycloalkoxy, mono- or poly-substituted (C 3 -C 8 )cycloalkoxy; (C 2 -C 8 )alkenyl, monosubstituted or polysubstituted (C 2 -C 8 ) alkenyl; (C 2 -C 8 ) alkynyl, mono- or polysubstituted (C 2 -C 8 ) alkynyl; (C 6 -C 20 ) aryl, monosubstituted or polysubstituted (C 6 -C 20 ) aryl; R 9 , R 10 Each is H, deuterium (D) or halogen, halogen is F or Cl; Wherein, X is -O- or -S- or -Se-; R 2 , R 5 , R 6 , R 7 Each is a "substituent" in the definition, (C 1 -C 8 ) alkyl, monosubstituted or polysubstituted (C 1 -C 8 ) alkyl; (C 1 -C 8 ) alkoxy, mono- or poly-substituted (C 1 -C 8 ) alkoxy; (C 3 -C 8 )cycloalkyl, mono- or poly-substituted (C 3 -C 8 )cycloalkyl; (C 3 -C 8 )cycloalkoxy, mono- or poly-substituted (C 3 -C 8 )cycloalkoxy; (C 2 -C 8 )alkenyl, monosubstituted or polysubstituted (C 2 -C 8 ) alkenyl; (C 2 -C 8 ) alkynyl, mono- or polysubstituted (C 2 -C 8 ) alkynyl; (C 6 -C 20 ) aryl, monosubstituted or polysubstituted (C 6 -C 20 ) aryl;; R 9 , R 10 Each is H, deuterium D or halogen, halogen is F or Cl; Where R 3 (Except -OH group in substituent) R 5 , R 6 , R 7 Each is a "substituent" in the definition, (C 1 -C 8 ) alkyl, monosubstituted or polysubstituted (C 1 -C 8 ) alkyl; (C 1 -C 8 ) alkoxy, mono- or poly-substituted (C 1 -C 8 ) alkoxy; (C 3 -C 8 )cycloalkyl, mono- or poly-substituted (C 3 -C 8 )cycloalkyl; (C 3 -C 8 )cycloalkoxy, mono- or poly-substituted (C 3 -C 8 )cycloalkoxy; (C 2 -C 8 )alkenyl, monosubstituted or polysubstituted (C 2 -C 8 ) alkenyl; (C 2 -C 8 ) alkynyl, mono- or polysubstituted (C 2 -C 8 ) alkynyl; (C 6 -C 20 ) aryl, monosubstituted or polysubstituted (C 6 -C 20 ) aryl; R 3 Except for the -OH group in the substituent); R 9 , R 10 Each is H, deuterium D or halogen, halogen is F or Cl; Where R 3 , R 5 (Except -OH in the substituent), R 2 , R 7 Each is a "substituent" in the definition, (C 1 -C 8 ) alkyl, monosubstituted or polysubstituted (C 1 -C 8 ) alkyl; (C 1 -C 8 ) alkoxy, mono- or poly-substituted (C 1 -C 8 ) alkoxy; (C 3 -C 8 )cycloalkyl, mono- or poly-substituted (C 3 -C 8 )cycloalkyl; (C 3 -C 8 )cycloalkoxy, mono- or poly-substituted (C 3 -C 8 )cycloalkoxy; (C 2 -C 8 )alkenyl, monosubstituted or polysubstituted (C 2 -C 8 ) alkenyl; (C 2 -C 8 ) alkynyl, mono- or polysubstituted (C 2 -C 8 ) alkynyl; (C 6 -C 20 ) aryl, monosubstituted or polysubstituted (C 6 -C 20 ) aryl; R 5 Exclude the -OH group in the substituent; R 9 , R 10 Each is H, deuterium D or halogen, and halogen is F or Cl.
10. The compound according to claim 8, Features: For example, formula 2-C 1 The compound shown is derived into a compound of formula 2-C 1 / a compound represented by formula 2-C 1 / b compound represented by formula 2-C 1 / c represented by the compound of formula 2-C 1 / d indicated compound; 11. A pharmaceutical composition, It is characterized in that The invention comprises a compound of formula 1 or a pharmaceutically acceptable salt thereof according to claim 1, and a pharmaceutically acceptable carrier.
12. Use of the nucleoside phosphate of the compound of formula 1 or a pharmaceutically acceptable salt thereof or the pharmaceutical composition as claimed in claim 1 in the preparation of a drug for inhibiting hepatitis B virus.
